Healthcare logistics market seen reaching $205 billion by 2035

The healthcare logistics market is projected to nearly double from $98.5 billion in 2025 to $205 billion by 2035, driven by biologics, tighter serialization rules and decentralized clinical trials. North America leads today, while Asia-Pacific is the fastest-growing region and Europe remains a major compliance-driven hub.

Why it matters: - Healthcare logistics is shifting from a cost center to a strategic capability as drug makers, trial sponsors and hospitals need more controlled, traceable and faster distribution. - The market’s growth is tied to biologics, cell and gene therapies, personalized medicine, decentralized trials and pandemic-preparedness investments. - Europe, North America and Asia-Pacific are being reshaped by regulatory mandates that require more digital verification and chain-of-custody control.

What happened: - The healthcare logistics market was valued at $98.5 billion in 2025 and is projected to reach $205.0 billion by 2035. - The forecast implies a 7.6% compound annual growth rate from 2026 through 2035. - Market Research Future published the outlook and supporting regional and segment estimates. - A sample report and full report are available through the report sample and the full report.

The details: - North America holds about 38% of global revenue, Europe about 28%, and Asia-Pacific is the fastest-growing region at a projected 9.2% CAGR. - Transportation is the largest service segment, with about 42% of global spend in 2025. - Air freight makes up about 15% of pharmaceutical transport by volume but more than 40% by value. - Warehousing and storage is the fastest-expanding infrastructure segment, growing at an 8.3% CAGR. - Value-added services such as packaging, labeling and regulatory documentation generated about $12.4 billion in 2025 and are growing at an 8.8% CAGR. - Distribution and fulfillment generated about $21.6 billion in 2025. - Pharmaceutical products account for more than 55% of application share in 2025. - Clinical trial logistics is the fastest-growing application, expanding at a 9.8% CAGR. - Pharmaceutical and biotechnology companies are the largest end-user group with about 48% share in 2025. - Retail and e-pharmacy is the fastest-growing end-user segment at a 9.4% CAGR. - The United States accounts for about 82% of North American share, and the US processes more than 4.7 billion prescriptions annually. - Europe’s logistics market is supported by GDP harmonization, cross-border serialization and biologics hub development. - Germany accounts for about 23% of Europe’s share, while the UK is growing at a 7.4% CAGR. - China holds about 35% of Asia-Pacific share, and India is growing at a 10.5% CAGR. - Brazil leads South America with about 58% regional share. - The Middle East and Africa region is growing at an 8.7% CAGR, with the UAE and Saudi Arabia as key hubs.

Between the lines: - Digital compliance is becoming a competitive requirement, not a back-office function, as serialization and track-and-trace rules spread across major markets. - The move toward decentralized and hybrid trials is increasing demand for residential delivery, real-time monitoring and return logistics. - Biologics are raising the cost and complexity of shipping because many require 2–8°C or even –80°C handling throughout transit. - The market remains moderately concentrated, with the top five players holding an estimated 28% to 35% of global revenue. - DHL Supply Chain & Global Forwarding, UPS Healthcare, FedEx Logistics, Kuehne+Nagel, McKesson, Cencora and Cardinal Health are among the largest operators.

What's next: - Logistics providers are likely to keep investing in temperature-controlled facilities, digital tracking tools and clinical-trial-focused networks. - Asia-Pacific should continue to outpace other regions as China, India and South Korea expand biologics production, exports and cold-chain infrastructure. - Recent moves, including UPS Healthcare’s $48 million cross-dock expansion and Kuehne+Nagel’s AI-enabled control tower upgrades, point to continued automation and network buildout. - Regulatory pressure is expected to keep driving technology upgrades as the US Drug Supply Chain Security Act and Europe’s Falsified Medicines Directive continue to shape distribution requirements.

The bottom line: - Healthcare logistics is becoming a higher-value, technology-heavy market built around compliance, temperature control and direct-to-patient delivery.